An Open-label Randomized Phase 3 Study of MK-2870 as a Single Agent and in Combination with Pembrolizumab Versus Treatment of Physician s Choice in Participants with HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer
This clinical study will evaluate MK-2870 either alone or in combination with pembrolizumab versus TPC in participants with HR+/HER2- (both HER2-zero and HER2-low) unresectable locally advanced or MBC, who have not been previously treatedwith chemotherapy in the metastatic setting.
An open-label randomized trial of zanidatamab with standard-of-care therapy against standard-of-care therapy alone for advanced HER2-positive biliary tract cancer (BTC)
This study is testing a new treatment called zanidatamab to see how well it works and how safe it is for people with a type of cancer called HER2-positive biliary tract cancer (BTC), which affects the gallbladder and bile ducts and cannot be removed by surgery or has spread to other parts of the body. Participants may receive up to two cycles of chemotherapy (cisplatin and gemcitabine, or “CisGem”) before being randomly assigned to one of two groups. In Group A, participants will get zanidatamab plus CisGem, with or without an immune therapy drug (like durvalumab or pembrolizumab). In Group B, participants will get CisGem, with or without the immune therapy drug. The treatment will continue until the cancer gets worse.
An Open-label Study to Evaluate the Safety Tolerability Pharmacokinetics and Pharmacodynamics of EDG-7500 in Adults with Hypertrophic Cardiomyopathy
The purpose of this study is to learn about the safety and tolerability of an investigational study drug called EDG-7500 for the treatment of hypertrophic cardiomyopathy (HCM). The study will also measure levels of study drug and any possible metabolites (break-down products of the study drug) and biological markers (biomarkers) in the blood. Biomarkers are substances in your blood that help us understand how the body is reacting to the study drug.
AN OPEN-LABEL TREATMENT WITH RANDOMIZATION OBSERVATION INVESTIGATOR-INITIATED STUDY ON THE DURATION AND EFFICACY OF JORNAY PM (METHYLPHENIDATE HYDROCHLORIDE EXTENDED-RELEASE CAPSULES) ON ADULT ADHD SYMPTOMS AND EXECUTIVE FUNCTION AND EMOTIONAL REGULATION THROUGHOUT THE DAY INTO EARLY EVENING
The purpose of this research study is to examine the efficacy of Jornay PM on Attention-Deficit/Hyperactivity Disorder (ADHD) symptoms and Executive Function throughout the day into early evening. This study will last approximately 11 weeks with will involve about 11 visits that are conducted both remote (WebEx/Telephone) and in the clinic.
ANBL1531: A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or Crizotinib Added to Intensive Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma (NBL) (IND# 134379)
Despite recent improvements in outcome for children with newly diagnosed high-risk neuroblastoma, cure rates remain unsatisfactory. Further, these gains have been the result of interventions during the Consolidation (tandem autologous stem cell transplant) and Post-Consolidation (dinutuximab immunotherapy) phases of treatment, while rates of disease control during Induction have not improved in recent COG trials. The current phase 3 trial seeks to improve the event-free survival (EFS) for children with high-risk neuroblastoma through early integration of promising novel targeted therapies: targeted radiopharmaceutical therapy with 131I-MIBG or the ALK inhibitor, crizotinib. After enrollment, patients will receive one cycle of Induction chemotherapy. Subsequent therapy will be based upon MIBG avidity and ALK status. Patients with MIBG-avid, ALK wild type (or ALK unknown) disease will be randomized to one of three arms: A) current COG recommended high-risk therapy including four more cycles of Induction chemotherapy and surgical resection of the primary tumor, Consolidation with tandem transplant and focal external beam radiation, and dinutuximab immunotherapy with isotretinoin; B) current COG recommended high-risk therapy with the addition of a block of 131I-MIBG after the third Induction cycle; or C) current COG recommended high-risk therapy with the addition of a block of 131I-MIBG after the third Induction cycle and substitution of busulfan / melphalan (BuMel) single autologous stem cell transplant in place of tandem transplant. Patients with MIBG non-avid, ALK wild type (or ALK unknown) disease will be non-randomly assigned to receive current COG recommended high-risk therapy without the addition of 131I-MIBG. Patients with ALK aberrant tumors (ALK tyrosine kinase mutation or ALK amplification) will be non-randomly assigned to receive crizotinib added to current COG recommended high-risk therapy. The primary endpoint is EFS and 774 eligible and evaluable patients are anticipated to enroll over approximately 5 years. Key secondary endpoints are toxicity, end-Induction response, and overall survival. Late effects of therapy including targeted therapies will be compared with late effects of current COG recommended treatment. Embedded correlative studies seek to understand predictors of benefit and resistance to 131I-MIBG and crizotinib.
Andrew W. Brotman, MD | NYU Langone Health
Andrew W. Brotman is senior advisor to CEO and Dean Alec C Kimmelman, MD, PhD.
Anesthesiology Doctors | NYU Langone Health
View all NYU Langone doctors who specialize in anesthesiology.
Angelman Syndrome Clinic | NYU Langone Health
The Angelman Syndrome Clinic at NYU Langone’s Comprehensive Epilepsy Center provides expert care for people with Angelman syndrome.
Angina with No Blockage | NYU Langone Health
NYU Langone doctors diagnose and treat chest discomfort (angina) with no blockage, also known as ischemia with no obstructive coronary artery disease (INOCA).
Anita Saltz Institute for Anxiety & Mood Disorders | NYU Langone Health
The Anita Saltz Institute for Anxiety and Mood Disorders at NYU Langone’s Child Study Center treats depression in children and adolescents.